Company intelligence / Profile preview

Caliway Biopharmaceuticals

Ownership: Public · 6919
Development stage: Phase 3

Overview

CBL-514, the lead candidate, has shown strong efficacy in reducing subcutaneous fat and treating Dercum's disease. In Phase IIb studies for non-invasive fat reduction, over 80% of subjects achieved at least a one-grade improvement with favorable safety. For Dercum's disease, CBL‑514 reduced lipoma size by >50% and improved pain scores significantly. The company has received FDA IND acceptance for further studies and initiated pivotal global trials.

Therapeutic areas: EndocrinologyRare DiseasesDermatologyMetabolic Disorders
Modalities: Small molecules
Industry: Biotech

Drug pipeline

6 assets

CBL-514

5 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Caliway Biopharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Caliway Biopharmaceuticals.

Explore the full profile